Exelixis, Inc. Earnings Recaps
Shares fell 6.8% as investors reacted negatively to the company's modest guidance revision citing slower-than-anticipated growth in the NET indication and more cautious near-term revenue ramp expectations.
Key takeaways
- Total revenues for Q2 2026 were approximately $629 million, with cabozantinib franchise net product revenues of $573 million.
- U.S. cabozantinib franchise sales grew about 10% year-over-year, while global cabozantinib revenues increased roughly 13% year-over-year.
- Guidance was lowered modestly due to a slower ramp in the NET indication reflecting patient population and histology characteristics.
- Gross-to-net deductions increased, with Q2 at 29.5%, driven by lower co-pay assistance offset partially by increased 340B utilization; full-year gross-to-net expected between 30%-31%.
- Management emphasized disciplined expense management and maintained free cash flow projections despite investment in R&D and pipeline expansion.
Exelixis shares rose 10.3% following a quarter that demonstrated solid revenue growth driven by cabozantinib and encouraging pipeline progress, reassuring investors on the near-term commercial momentum and long-term opportunity.
Key takeaways
- U.S. cabozantinib franchise net product revenues increased 8% year-over-year to $555 million.
- Global cabozantinib franchise revenues rose 12.5% year-over-year to $764 million, reflecting broad international uptake.
- The ZANZA franchise is advancing rapidly, with an NDA under regulatory review for third-line colorectal cancer and seven pivotal trials ongoing or planned.
- Total revenues for the quarter were approximately $611 million, with operating expenses declining slightly sequentially to about $359 million.
- Gross-to-net deductions increased due to higher 340B volume, Medicare Part D discounts, and co-pay assistance, pressuring margins but not outweighing overall revenue gains.
Exelixis delivered strong third-quarter results, characterized by robust revenue growth driven by the success of cabozantinib and early achievements for zanzalintinib, setting the stage for future growth.
Key takeaways
- Cabozantinib U.S. net product revenues rose 14% year-over-year to $543 million, maintaining its leadership in the TKI market for renal cell carcinoma (RCC).
- Global cabozantinib revenues reached approximately $739 million, bolstered by a 50% increase in demand within the neuroendocrine tumor (NET) segment.
- Zanzalintinib is gaining momentum with seven pivotal trials underway; recent positive results in colorectal cancer (CRC) suggest potential regulatory submissions soon.
- The expansion of the GI sales team aims to accelerate growth in the CABINET indication, enhancing the company’s commercial footprint.
- Exelixis is committed to a disciplined capital allocation strategy while progressing its diverse R&D pipeline for sustained long-term value creation.
Exelixis delivered strong second-quarter performance in 2025, with cabozantinib franchise net revenues growing 19% year-over-year to $520 million, reflecting robust commercial demand.
Key takeaways
- Cabozantinib's U.S. net product revenues reached $520 million, driven by strong demand and a successful rollout of new indications.
- Zanzalintinib is advancing as a promising oncology franchise, with pivotal trials underway and positive results from STELLAR-303 expected to support an expedited regulatory filing.
- The early-stage pipeline is progressing rapidly, with several potential new therapies entering clinical evaluation, maintaining a focus on strategic capital allocation for development priorities.
- Exelixis plans to continue share repurchases when stock is undervalued, while actively pursuing business development opportunities for high-potential assets.